Continuing the recent frenzy of dealmaking activity in the hepatitis C virus (HCV) space, Enanta Pharmaceuticals Inc. is expected to announce Tuesday morning that it licensed preclinical NS5A inhibitor EDP-239 to Novartis AG in a deal worth up to $440 million.